ICE COLD-PCR Data Highlights Clinical Potential of the “Blood
Using Transgenomic’s ultrasensitive ICE COLD-PCR technology, investigators analyzed blood plasma samples collected from patients (n=60) with colorectal cancer, melanoma, non-small cell lung cancer and several other cancers, and compared them to corresponding samples taken from tumor tissue. Results demonstrated a 79% concordance between the mutational status detected by analysis of cfDNA and tumor tissue for patients whose tumors carried KRAS gene mutations and a 68% concordance for patients whose tumors carried BRAF gene mutations. These findings demonstrate the clinical relevance and utility of analyzing cfDNA in blood to detect low level mutations as an alternative to the far more invasive and difficult-to-conduct tissue biopsy.
The study, “BRAF and KRAS Mutation Testing in Cell-Free DNA and Circulating Tumor Cells from Blood of Patients with Metastatic Cancers” (Abstract #C203, Poster Session C: Novel Assay Technology 2), was presented by
“The results of our analysis indicate ICE COLD-PCR is an informative technique with the potential to help us guide therapeutic strategies among our patients with metastatic cancer,” said
“The broad use of ICE COLD-PCR, and its ability to detect low-level tumor mutations in blood, has the potential to revolutionize cancer screening, diagnosis, monitoring, and treatment selection,” said
This study, along with others at leading institutes, continues to also explore concordance rates between tumor tissue and circulating tumor cells (CTCs) isolated from patients, and demonstrates a low level of concordance.